Co-Authors
This is a "connection" page, showing publications co-authored by Shaji Sebastian and Christopher Lamb.
Connection Strength
0.976
-
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Aliment Pharmacol Ther. 2021 06; 53(11):1236-1240.
Score: 0.237
-
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021 04; 6(4):271-281.
Score: 0.232
-
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterol. 2020; 11(5):343-350.
Score: 0.222
-
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021 10; 70(10):1884-1893.
Score: 0.059
-
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021 05; 70(5):865-875.
Score: 0.058
-
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021 03; 6(3):218-224.
Score: 0.058
-
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020 10; 69(10):1769-1777.
Score: 0.055
-
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020 06; 69(6):984-990.
Score: 0.055